Skip to main content
Premium Trial:

Request an Annual Quote

German Software Co. Receives Grant to Develop New Capabilities

NEW YORK, Oct. 8 – Genomatix Software, a German bioinformatics company, said on Monday it had received a grant of 1.3 million Deutschmarks, or roughly $612,600, from the German government to develop gene-regulation software.

The German Federal Ministry of Education and Research awarded the grant as part of a program entitled “Bioinformatics for the Functional Analysis of Mammalian Genomes.” Genomatix said the grant would be used to enhance its efforts to identify and annotate mammalian promoters.

“Promoters are the turntable of life,” Thomas Werner, CEO of Genomatix, said in a statement. “We are going to close the gap between the terabyte of existing experimental information about gene regulation and its molecular basis on DNA level.”

Promoters are the final processors of transcription signals. These DNA sequence regions are located around a gene’s transcription start site.

Genomatix has analyzed the human genome for promoters and created a database with over 24,000 unique human promoters.

The company has also developed several software tools to analyze and predict promoters in the human genome.

The Scan

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.

New Insights Into TP53-Driven Cancer

Researchers examine in Nature how TP53 mutations arise and spark tumor development.

Mapping Single-Cell Genomic, Transcriptomic Landscapes of Colorectal Cancer

In Genome Medicine, researchers present a map of single-cell genomic and transcriptomic landscapes of primary and metastatic colorectal cancer.

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.